A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics

Overview

Journal CPT Pharmacometrics Syst Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2020 Feb 10

PMID 32036626

Citations 6

Authors

Jiajie Yu

Nina Wang

Matts Kagedal

Affiliations

Soon will be listed here.

Abstract

Progression-free survival (PFS) has been increasingly used as a primary endpoint for early clinical development. The aim of the present work was to develop a model where target lesion dynamics and risk for nontarget progression are jointly modeled for predicting PFS. The model was developed based on a pooled platinum-resistant ovarian cancer dataset comprising four different treatments and a wide range of dose levels. The target lesion progression was derived from tumor growth dynamics based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The nontarget progression hazard was correlated to the first derivative of target lesion tumor size with respect to time. The PFS time was determined by the first occurring event, target lesion progression, or nontarget progression. The final joint model not only captured target lesion tumor growth dynamics but also predicted PFS well. A similar approach can potentially be used to predict PFS in future oncology studies.

Citing Articles

A novel Bayesian generative approach for estimating tumor dynamics from published studies.

Pourzanjani A, Modi S, Connarn J, Zhang X, Upreti V, Lin C CPT Pharmacometrics Syst Pharmacol. 2024; 13(8):1341-1353.

PMID: 38778515 PMC: 11330188. DOI: 10.1002/psp4.13163.

Segmentation of patients with small cell lung cancer into responders and non-responders using the optimal cross-validation technique.

Majd E, Xing L, Zhang X BMC Med Res Methodol. 2024; 24(1):83.

PMID: 38589775 PMC: 11000309. DOI: 10.1186/s12874-024-02185-7.

Joint modeling of tumor dynamics and progression-free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I-II trials.

Cerou M, Thai H, Deyme L, Fliscounakis-Huynh S, Comets E, Cohen P CPT Pharmacometrics Syst Pharmacol. 2024; 13(6):941-953.

PMID: 38558299 PMC: 11179707. DOI: 10.1002/psp4.13128.

Knowledge-based mechanistic modeling accurately predicts disease progression with gefitinib in EGFR-mutant lung adenocarcinoma.

LHostis A, Palgen J, Perrillat-Mercerot A, Peyronnet E, Jacob E, Bosley J NPJ Syst Biol Appl. 2023; 9(1):37.

PMID: 37524705 PMC: 10390488. DOI: 10.1038/s41540-023-00292-7.

Model-informed drug development of autologous CAR-T cell therapy: Strategies to optimize CAR-T cell exposure leveraging cell kinetic/dynamic modeling.

Mc Laughlin A, Milligan P, Yee C, Bergstrand M CPT Pharmacometrics Syst Pharmacol. 2023; 12(11):1577-1590.

PMID: 37448343 PMC: 10681459. DOI: 10.1002/psp4.13011.

References

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Monk B, Herzog T, Kaye S, Krasner C, Vermorken J, Muggia F . Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010; 28(19):3107-14. DOI: 10.1200/JCO.2009.25.4037. View

Lindbom L, Pihlgren P, Jonsson E, Jonsson N . PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005; 79(3):241-57. DOI: 10.1016/j.cmpb.2005.04.005. View

Bruno R, Mercier F, Claret L . Evaluation of tumor size response metrics to predict survival in oncology clinical trials. Clin Pharmacol Ther. 2014; 95(4):386-93. DOI: 10.1038/clpt.2014.4. View

Claret L, Gupta M, Han K, Joshi A, Sarapa N, He J . Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer. J Clin Oncol. 2013; 31(17):2110-4. DOI: 10.1200/JCO.2012.45.0973. View

Anagnostou V, Yarchoan M, Hansen A, Wang H, Verde F, Sharon E . Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. Clin Cancer Res. 2017; 23(17):4959-4969. PMC: 5735844. DOI: 10.1158/1078-0432.CCR-16-3065. View

Keizer R, van Benten M, Beijnen J, Schellens J, Huitema A . Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2010; 101(1):72-9. DOI: 10.1016/j.cmpb.2010.04.018. View

Lim H, Sun W, Parivar K, Wang D . Predicting Overall Survival and Progression-Free Survival Using Tumor Dynamics in Advanced Breast Cancer Patients. AAPS J. 2019; 21(2):22. DOI: 10.1208/s12248-018-0290-x. View

Gordon A, Fleagle J, GUTHRIE D, Parkin D, Gore M, Lacave A . Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001; 19(14):3312-22. DOI: 10.1200/JCO.2001.19.14.3312. View

10.

Zecchin C, Gueorguieva I, Enas N, Friberg L . Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer. Br J Clin Pharmacol. 2016; 82(3):717-27. PMC: 5338128. DOI: 10.1111/bcp.12994. View

11.

Wahlby U, Jonsson E, Karlsson M . Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001; 28(3):231-52. DOI: 10.1023/a:1011527125570. View

12.

Claret L, Lu J, Sun Y, Bruno R . Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer. Cancer Chemother Pharmacol. 2010; 66(6):1141-9. DOI: 10.1007/s00280-010-1449-z. View

13.

Banerjee S, Oza A, Birrer M, Hamilton E, Hasan J, Leary A . Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018; 29(4):917-923. DOI: 10.1093/annonc/mdy023. View

14.

Claret L, Girard P, Hoff P, Van Cutsem E, Zuideveld K, Jorga K . Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol. 2009; 27(25):4103-8. DOI: 10.1200/JCO.2008.21.0807. View

15.

Beal S . Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2002; 28(5):481-504. DOI: 10.1023/a:1012299115260. View

16.

Wang Y, Sung C, Dartois C, Ramchandani R, Booth B, Rock E . Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther. 2009; 86(2):167-74. DOI: 10.1038/clpt.2009.64. View

17.

Claret L, Jin J, Ferte C, Winter H, Girish S, Stroh M . A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics. Clin Cancer Res. 2018; 24(14):3292-3298. DOI: 10.1158/1078-0432.CCR-17-3662. View

18.

Herzog T, Ison G, Alvarez R, Balasubramaniam S, Armstrong D, Beaver J . FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper. Gynecol Oncol. 2017; 147(1):3-10. DOI: 10.1016/j.ygyno.2017.08.012. View

19.

Liu J, Moore K, Birrer M, Berlin S, Matulonis U, Infante J . Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016; 27(11):2124-2130. DOI: 10.1093/annonc/mdw401. View